Filament Health Corp (FH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Filament Health Corp (FH) has a cash flow conversion efficiency ratio of -0.228x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-221.75K ≈ $-160.41K USD) by net assets (CA$974.38K ≈ $704.85K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Filament Health Corp (FH) total market value for the company's overall valuation and market capitalisation.
Filament Health Corp - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Filament Health Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Filament Health Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Filament Health Corp ranked by their cash flow conversion efficiency. See Filament Health Corp debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Starbreeze AB (publ)
ST:STAR-A
|
-0.015x |
|
Alliance Mining Corp
V:ALM
|
0.002x |
|
SHF Holdings Inc
NASDAQ:SHFS
|
-406.953x |
|
QURI-MAYU DEVELOPMENTS
F:JR9
|
-0.031x |
|
Jaguar Animal Health Inc
NASDAQ:JAGX
|
-1.085x |
|
Altech Batteries Ltd
AU:ATC
|
-0.199x |
|
KINGS ENTERTAINMENT GROUP
F:L12
|
N/A |
|
Therma Bright Inc
V:THRM
|
0.026x |
Annual Cash Flow Conversion Efficiency for Filament Health Corp (2020–2024)
The table below shows the annual cash flow conversion efficiency of Filament Health Corp from 2020 to 2024. View FH stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$1.75 Million ≈ $1.26 Million |
CA$-2.29 Million ≈ $-1.66 Million |
-1.310x | +22.06% |
| 2023-12-31 | CA$2.49 Million ≈ $1.80 Million |
CA$-4.19 Million ≈ $-3.03 Million |
-1.681x | -38.80% |
| 2022-12-31 | CA$3.19 Million ≈ $2.31 Million |
CA$-3.87 Million ≈ $-2.80 Million |
-1.211x | -270.68% |
| 2021-12-31 | CA$16.55 Million ≈ $11.97 Million |
CA$-5.41 Million ≈ $-3.91 Million |
-0.327x | -247.81% |
| 2020-12-31 | CA$813.64K ≈ $588.58K |
CA$-76.42K ≈ $-55.28K |
-0.094x | -- |
About Filament Health Corp
Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. The company's leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. It also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, the company provide… Read more